1. Barun, B, Gabelic, T, Adamec, I, et al. Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Mult Scler Relat Disord 2020; 48: 102704.
Google Scholar | Crossref | Medline2. Novi, G, Bovis, F, Fabbri, S, et al. Tailoring B cell depletion therapy in MS according to memory B cell monitoring. Neurol Neuroimmunol Neuroinflamm 2020; 7(5): e845.
Google Scholar | Crossref | Medline3. Rolfes, L, Pawlitzki, M, Pfeuffer, S, et al. Ocrelizumab extended interval dosing in multiple sclerosis in times of COVID-19. Neurol Neuroimmunol Neuroinflamm 2021; 8(5): e1035.
Google Scholar | Crossref | Medline4. Tazza, F, Lapucci, C, Cellerino, M, et al. Personalizing ocrelizumab treatment in multiple sclerosis: What can we learn from Sars-Cov2 pandemic? J Neurol Sci 2021; 427: 117501.
Google Scholar | Crossref | Medline5. van Lierop, ZY, Toorop, AA, van Ballegoij, WJ, et al. Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. Mult Scler. Epub ahead of print 9 July 2021. DOI: 10.1177/13524585211028833.
Google Scholar | SAGE Journals6. Vollmer, BL, Wallach, AI, Corboy, JR, et al. Serious safety events in rituximab-treated multiple sclerosis and related disorders. Ann Clin Transl Neurol 2020; 7(9): 1477–1487.
Google Scholar | Crossref | Medline7. Langer-Gould, A, Smith, JB, Li, BH, et al. Multiple sclerosis, rituximab, and COVID-19. Ann Clin Transl Neurol 2021; 8: 938–943.
Google Scholar | Crossref | Medline8. Toorop, AA, van Lierop, ZYGJ, Strijbis, EMM, et al. The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Mult Scler Relat Disord. Epub ahead of print 1 November 2021. DOI: 10.1016/j.msard.2021.103364.
Google Scholar | Crossref9. Gibiansky, E, Petry, C, Mercier, F, et al. Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol 2021; 87: 2511–2520.
Google Scholar | Crossref | Medline10. Baker, D, Pryce, G, James, LK, et al. The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis. Mult Scler Relat Disord 2020; 44: 102279.
Google Scholar | Crossref | Medline